DB00255Diethylstilbestrol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB00269Chlorotrianisene may increase the thrombogenic activities of Telisotuzumab vedotin.
DB00286Conjugated estrogens may increase the thrombogenic activities of Telisotuzumab vedotin.
DB00655Estrone may increase the thrombogenic activities of Telisotuzumab vedotin.
DB00783Estradiol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB00890Dienestrol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB00977Ethinylestradiol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB01357Mestranol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB04573Estriol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB04574Estrone sulfate may increase the thrombogenic activities of Telisotuzumab vedotin.
DB04575Quinestrol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB07931Hexestrol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB09070Tibolone may increase the thrombogenic activities of Telisotuzumab vedotin.
DB09317Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Telisotuzumab vedotin.
DB09318Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Telisotuzumab vedotin.
DB09369Polyestradiol phosphate may increase the thrombogenic activities of Telisotuzumab vedotin.
DB09381Esterified estrogens may increase the thrombogenic activities of Telisotuzumab vedotin.
DB11478Zeranol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB11674Equol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB12487Promestriene may increase the thrombogenic activities of Telisotuzumab vedotin.
DB13143Methallenestril may increase the thrombogenic activities of Telisotuzumab vedotin.
DB13386Epimestrol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB13418Moxestrol may increase the thrombogenic activities of Telisotuzumab vedotin.
DB13952Estradiol acetate may increase the thrombogenic activities of Telisotuzumab vedotin.
DB13953Estradiol benzoate may increase the thrombogenic activities of Telisotuzumab vedotin.
DB13954Estradiol cypionate may increase the thrombogenic activities of Telisotuzumab vedotin.
DB13956Estradiol valerate may increase the thrombogenic activities of Telisotuzumab vedotin.
DB15334Biochanin A may increase the thrombogenic activities of Telisotuzumab vedotin.
DB15335Formononetin may increase the thrombogenic activities of Telisotuzumab vedotin.
DB00002The risk or severity of adverse effects can be increased when Cetuximab is combined with Telisotuzumab vedotin.
DB00028The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Telisotuzumab vedotin.
DB00043The risk or severity of adverse effects can be increased when Omalizumab is combined with Telisotuzumab vedotin.
DB00051The risk or severity of adverse effects can be increased when Adalimumab is combined with Telisotuzumab vedotin.
DB00054The risk or severity of adverse effects can be increased when Abciximab is combined with Telisotuzumab vedotin.
DB00056The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Telisotuzumab vedotin.
DB00057The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Telisotuzumab vedotin.
DB00065The risk or severity of adverse effects can be increased when Infliximab is combined with Telisotuzumab vedotin.
DB00072The risk or severity of adverse effects can be increased when Trastuzumab is combined with Telisotuzumab vedotin.
DB00073The risk or severity of adverse effects can be increased when Rituximab is combined with Telisotuzumab vedotin.
DB00074The risk or severity of adverse effects can be increased when Basiliximab is combined with Telisotuzumab vedotin.
DB00075The risk or severity of adverse effects can be increased when Muromonab is combined with Telisotuzumab vedotin.
DB00076The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Telisotuzumab vedotin.
DB00078The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Telisotuzumab vedotin.
DB00081The risk or severity of adverse effects can be increased when Tositumomab is combined with Telisotuzumab vedotin.
DB00087The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Telisotuzumab vedotin.
DB00089The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Telisotuzumab vedotin.
DB00095The risk or severity of adverse effects can be increased when Efalizumab is combined with Telisotuzumab vedotin.
DB00098The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Telisotuzumab vedotin.
DB00108The risk or severity of adverse effects can be increased when Natalizumab is combined with Telisotuzumab vedotin.
DB00110The risk or severity of adverse effects can be increased when Palivizumab is combined with Telisotuzumab vedotin.
DB00111The risk or severity of adverse effects can be increased when Daclizumab is combined with Telisotuzumab vedotin.
DB00112The risk or severity of adverse effects can be increased when Bevacizumab is combined with Telisotuzumab vedotin.
DB00113The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Telisotuzumab vedotin.
DB01257The risk or severity of adverse effects can be increased when Eculizumab is combined with Telisotuzumab vedotin.
DB01269The risk or severity of adverse effects can be increased when Panitumumab is combined with Telisotuzumab vedotin.
DB01270The risk or severity of adverse effects can be increased when Ranibizumab is combined with Telisotuzumab vedotin.
DB04901The risk or severity of adverse effects can be increased when Galiximab is combined with Telisotuzumab vedotin.
DB04949The risk or severity of adverse effects can be increased when Pexelizumab is combined with Telisotuzumab vedotin.
DB04956The risk or severity of adverse effects can be increased when Afelimomab is combined with Telisotuzumab vedotin.
DB04958The risk or severity of adverse effects can be increased when Epratuzumab is combined with Telisotuzumab vedotin.
DB04962The risk or severity of adverse effects can be increased when Bectumomab is combined with Telisotuzumab vedotin.
DB04964The risk or severity of adverse effects can be increased when Oregovomab is combined with Telisotuzumab vedotin.
DB04988The risk or severity of adverse effects can be increased when IGN311 is combined with Telisotuzumab vedotin.
DB05006The risk or severity of adverse effects can be increased when Adecatumumab is combined with Telisotuzumab vedotin.
DB05097The risk or severity of adverse effects can be increased when Labetuzumab is combined with Telisotuzumab vedotin.
DB05101The risk or severity of adverse effects can be increased when Matuzumab is combined with Telisotuzumab vedotin.
DB05111The risk or severity of adverse effects can be increased when Fontolizumab is combined with Telisotuzumab vedotin.
DB05136The risk or severity of adverse effects can be increased when Bavituximab is combined with Telisotuzumab vedotin.
DB05139The risk or severity of adverse effects can be increased when CR002 is combined with Telisotuzumab vedotin.
DB05209The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Telisotuzumab vedotin.
DB05304The risk or severity of adverse effects can be increased when Girentuximab is combined with Telisotuzumab vedotin.
DB05336The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Telisotuzumab vedotin.
DB05405The risk or severity of adverse effects can be increased when XTL-001 is combined with Telisotuzumab vedotin.
DB05437The risk or severity of adverse effects can be increased when NAV 1800 is combined with Telisotuzumab vedotin.
DB05459The risk or severity of adverse effects can be increased when Briakinumab is combined with Telisotuzumab vedotin.
DB05496The risk or severity of adverse effects can be increased when Otelixizumab is combined with Telisotuzumab vedotin.
DB05545The risk or severity of adverse effects can be increased when AMG 108 is combined with Telisotuzumab vedotin.
DB05550The risk or severity of adverse effects can be increased when Iratumumab is combined with Telisotuzumab vedotin.
DB05555The risk or severity of adverse effects can be increased when Enokizumab is combined with Telisotuzumab vedotin.
DB05578The risk or severity of adverse effects can be increased when Ramucirumab is combined with Telisotuzumab vedotin.
DB05595The risk or severity of adverse effects can be increased when Farletuzumab is combined with Telisotuzumab vedotin.
DB05656The risk or severity of adverse effects can be increased when Veltuzumab is combined with Telisotuzumab vedotin.
DB05679The risk or severity of adverse effects can be increased when Ustekinumab is combined with Telisotuzumab vedotin.
DB05773The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Telisotuzumab vedotin.
DB05793The risk or severity of adverse effects can be increased when PRO-542 is combined with Telisotuzumab vedotin.
DB05797The risk or severity of adverse effects can be increased when TNX-901 is combined with Telisotuzumab vedotin.
DB05889The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Telisotuzumab vedotin.
DB05892The risk or severity of adverse effects can be increased when RI 624 is combined with Telisotuzumab vedotin.
DB05915The risk or severity of adverse effects can be increased when MYO-029 is combined with Telisotuzumab vedotin.
DB05916The risk or severity of adverse effects can be increased when CT-011 is combined with Telisotuzumab vedotin.
DB05941The risk or severity of adverse effects can be increased when Leronlimab is combined with Telisotuzumab vedotin.
DB05996The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Telisotuzumab vedotin.
DB06043The risk or severity of adverse effects can be increased when Olaratumab is combined with Telisotuzumab vedotin.
DB06049The risk or severity of adverse effects can be increased when IPH 2101 is combined with Telisotuzumab vedotin.
DB06050The risk or severity of adverse effects can be increased when TB-402 is combined with Telisotuzumab vedotin.
DB06081The risk or severity of adverse effects can be increased when Caplacizumab is combined with Telisotuzumab vedotin.
DB06101The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Telisotuzumab vedotin.
DB06116The risk or severity of adverse effects can be increased when Eldelumab is combined with Telisotuzumab vedotin.
DB06162The risk or severity of adverse effects can be increased when Lumiliximab is combined with Telisotuzumab vedotin.
DB06168The risk or severity of adverse effects can be increased when Canakinumab is combined with Telisotuzumab vedotin.
DB06186The risk or severity of adverse effects can be increased when Ipilimumab is combined with Telisotuzumab vedotin.
DB06192The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Telisotuzumab vedotin.
DB06241The risk or severity of adverse effects can be increased when Clenoliximab is combined with Telisotuzumab vedotin.
DB06273The risk or severity of adverse effects can be increased when Tocilizumab is combined with Telisotuzumab vedotin.
DB06304The risk or severity of adverse effects can be increased when BIIB015 is combined with Telisotuzumab vedotin.
DB06305The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Telisotuzumab vedotin.
DB06310The risk or severity of adverse effects can be increased when Motavizumab is combined with Telisotuzumab vedotin.
DB06317The risk or severity of adverse effects can be increased when Elotuzumab is combined with Telisotuzumab vedotin.
DB06318The risk or severity of adverse effects can be increased when AVE9633 is combined with Telisotuzumab vedotin.
DB06322The risk or severity of adverse effects can be increased when Carotuximab is combined with Telisotuzumab vedotin.
DB06324The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Telisotuzumab vedotin.
DB06342The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Telisotuzumab vedotin.
DB06343The risk or severity of adverse effects can be increased when Teprotumumab is combined with Telisotuzumab vedotin.
DB06360The risk or severity of adverse effects can be increased when Lucatumumab is combined with Telisotuzumab vedotin.
DB06366The risk or severity of adverse effects can be increased when Pertuzumab is combined with Telisotuzumab vedotin.
DB06371The risk or severity of adverse effects can be increased when Siplizumab is combined with Telisotuzumab vedotin.
DB06467The risk or severity of adverse effects can be increased when Apolizumab is combined with Telisotuzumab vedotin.
DB06474The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Telisotuzumab vedotin.
DB06550The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Telisotuzumab vedotin.
DB06557The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Telisotuzumab vedotin.
DB06599The risk or severity of adverse effects can be increased when Lexatumumab is combined with Telisotuzumab vedotin.
DB06602The risk or severity of adverse effects can be increased when Reslizumab is combined with Telisotuzumab vedotin.
DB06606The risk or severity of adverse effects can be increased when Teplizumab is combined with Telisotuzumab vedotin.
DB06607The risk or severity of adverse effects can be increased when Catumaxomab is combined with Telisotuzumab vedotin.
DB06612The risk or severity of adverse effects can be increased when Mepolizumab is combined with Telisotuzumab vedotin.
DB06643The risk or severity of adverse effects can be increased when Denosumab is combined with Telisotuzumab vedotin.
DB06647The risk or severity of adverse effects can be increased when Volociximab is combined with Telisotuzumab vedotin.
DB06650The risk or severity of adverse effects can be increased when Ofatumumab is combined with Telisotuzumab vedotin.
DB06674The risk or severity of adverse effects can be increased when Golimumab is combined with Telisotuzumab vedotin.
DB08870The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Telisotuzumab vedotin.
DB08879The risk or severity of adverse effects can be increased when Belimumab is combined with Telisotuzumab vedotin.
DB08902The risk or severity of adverse effects can be increased when Raxibacumab is combined with Telisotuzumab vedotin.
DB08904The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Telisotuzumab vedotin.
DB08935The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Telisotuzumab vedotin.
DB09029The risk or severity of adverse effects can be increased when Secukinumab is combined with Telisotuzumab vedotin.
DB09033The risk or severity of adverse effects can be increased when Vedolizumab is combined with Telisotuzumab vedotin.
DB09035The risk or severity of adverse effects can be increased when Nivolumab is combined with Telisotuzumab vedotin.
DB09036The risk or severity of adverse effects can be increased when Siltuximab is combined with Telisotuzumab vedotin.
DB09037The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Telisotuzumab vedotin.
DB09045The risk or severity of adverse effects can be increased when Dulaglutide is combined with Telisotuzumab vedotin.
DB09052The risk or severity of adverse effects can be increased when Blinatumomab is combined with Telisotuzumab vedotin.
DB09057The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Telisotuzumab vedotin.
DB09077The risk or severity of adverse effects can be increased when Dinutuximab is combined with Telisotuzumab vedotin.
DB09105The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Telisotuzumab vedotin.
DB09264The risk or severity of adverse effects can be increased when Idarucizumab is combined with Telisotuzumab vedotin.
DB09302The risk or severity of adverse effects can be increased when Alirocumab is combined with Telisotuzumab vedotin.
DB09303The risk or severity of adverse effects can be increased when Evolocumab is combined with Telisotuzumab vedotin.
DB09312The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Telisotuzumab vedotin.
DB09331The risk or severity of adverse effects can be increased when Daratumumab is combined with Telisotuzumab vedotin.
DB09559The risk or severity of adverse effects can be increased when Necitumumab is combined with Telisotuzumab vedotin.
DB11569The risk or severity of adverse effects can be increased when Ixekizumab is combined with Telisotuzumab vedotin.
DB11580The risk or severity of adverse effects can be increased when Ravulizumab is combined with Telisotuzumab vedotin.
DB11595The risk or severity of adverse effects can be increased when Atezolizumab is combined with Telisotuzumab vedotin.
DB11604The risk or severity of adverse effects can be increased when Tetanus Immune Globulin is combined with Telisotuzumab vedotin.
DB11608The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Telisotuzumab vedotin.
DB11621The risk or severity of adverse effects can be increased when Human Varicella-Zoster Immune Globulin is combined with Telisotuzumab vedotin.
DB11646The risk or severity of adverse effects can be increased when Conatumumab is combined with Telisotuzumab vedotin.
DB11657The risk or severity of adverse effects can be increased when Tabalumab is combined with Telisotuzumab vedotin.
DB11680The risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Telisotuzumab vedotin.
DB11685The risk or severity of adverse effects can be increased when Figitumumab is combined with Telisotuzumab vedotin.
DB11714The risk or severity of adverse effects can be increased when Durvalumab is combined with Telisotuzumab vedotin.
DB11715The risk or severity of adverse effects can be increased when Bapineuzumab is combined with Telisotuzumab vedotin.
DB11731The risk or severity of adverse effects can be increased when Depatuxizumab mafodotin is combined with Telisotuzumab vedotin.
DB11746The risk or severity of adverse effects can be increased when Onartuzumab is combined with Telisotuzumab vedotin.
DB11756The risk or severity of adverse effects can be increased when Solanezumab is combined with Telisotuzumab vedotin.
DB11767The risk or severity of adverse effects can be increased when Sarilumab is combined with Telisotuzumab vedotin.
DB11771The risk or severity of adverse effects can be increased when Tremelimumab is combined with Telisotuzumab vedotin.
DB11776The risk or severity of adverse effects can be increased when Brodalumab is combined with Telisotuzumab vedotin.
DB11803The risk or severity of adverse effects can be increased when Sirukumab is combined with Telisotuzumab vedotin.
DB11826The risk or severity of adverse effects can be increased when Lampalizumab is combined with Telisotuzumab vedotin.
DB11834The risk or severity of adverse effects can be increased when Guselkumab is combined with Telisotuzumab vedotin.
DB11840The risk or severity of adverse effects can be increased when Dalotuzumab is combined with Telisotuzumab vedotin.
DB11849The risk or severity of adverse effects can be increased when Emibetuzumab is combined with Telisotuzumab vedotin.
DB11850The risk or severity of adverse effects can be increased when Ublituximab is combined with Telisotuzumab vedotin.
DB11856The risk or severity of adverse effects can be increased when Ligelizumab is combined with Telisotuzumab vedotin.
DB11857The risk or severity of adverse effects can be increased when Seribantumab is combined with Telisotuzumab vedotin.
DB11862The risk or severity of adverse effects can be increased when Landogrozumab is combined with Telisotuzumab vedotin.
DB11866The risk or severity of adverse effects can be increased when Romosozumab is combined with Telisotuzumab vedotin.
DB11884The risk or severity of adverse effects can be increased when Vadastuximab Talirine is combined with Telisotuzumab vedotin.
DB11914The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Telisotuzumab vedotin.
DB11930The risk or severity of adverse effects can be increased when Varlilumab is combined with Telisotuzumab vedotin.
DB11945The risk or severity of adverse effects can be increased when Avelumab is combined with Telisotuzumab vedotin.
DB11959The risk or severity of adverse effects can be increased when Crenezumab is combined with Telisotuzumab vedotin.
DB11972The risk or severity of adverse effects can be increased when Rilotumumab is combined with Telisotuzumab vedotin.
DB11976The risk or severity of adverse effects can be increased when Anifrolumab is combined with Telisotuzumab vedotin.
DB11988The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Telisotuzumab vedotin.
DB12023The risk or severity of adverse effects can be increased when Benralizumab is combined with Telisotuzumab vedotin.
DB12034The risk or severity of adverse effects can be increased when Gantenerumab is combined with Telisotuzumab vedotin.
DB12053The risk or severity of adverse effects can be increased when Visilizumab is combined with Telisotuzumab vedotin.
DB12077The risk or severity of adverse effects can be increased when Urelumab is combined with Telisotuzumab vedotin.
DB12089The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Telisotuzumab vedotin.
DB12090The risk or severity of adverse effects can be increased when Patritumab is combined with Telisotuzumab vedotin.
DB12102The risk or severity of adverse effects can be increased when Fulranumab is combined with Telisotuzumab vedotin.
DB12104The risk or severity of adverse effects can be increased when Tarextumab is combined with Telisotuzumab vedotin.
DB12118The risk or severity of adverse effects can be increased when Sotatercept is combined with Telisotuzumab vedotin.
DB12119The risk or severity of adverse effects can be increased when Gevokizumab is combined with Telisotuzumab vedotin.
DB12142The risk or severity of adverse effects can be increased when Duligotuzumab is combined with Telisotuzumab vedotin.
DB12152The risk or severity of adverse effects can be increased when Simtuzumab is combined with Telisotuzumab vedotin.
DB12157The risk or severity of adverse effects can be increased when Fasinumab is combined with Telisotuzumab vedotin.
DB12159The risk or severity of adverse effects can be increased when Dupilumab is combined with Telisotuzumab vedotin.
DB12169The risk or severity of adverse effects can be increased when Tralokinumab is combined with Telisotuzumab vedotin.
DB12189The risk or severity of adverse effects can be increased when Etrolizumab is combined with Telisotuzumab vedotin.
DB12202The risk or severity of adverse effects can be increased when Zalutumumab is combined with Telisotuzumab vedotin.
DB12205The risk or severity of adverse effects can be increased when Ganitumab is combined with Telisotuzumab vedotin.
DB12213The risk or severity of adverse effects can be increased when Etaracizumab is combined with Telisotuzumab vedotin.
DB12240The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Telisotuzumab vedotin.
DB12246The risk or severity of adverse effects can be increased when Inclacumab is combined with Telisotuzumab vedotin.
DB12250The risk or severity of adverse effects can be increased when Cixutumumab is combined with Telisotuzumab vedotin.
DB12261The risk or severity of adverse effects can be increased when Ascrinvacumab is combined with Telisotuzumab vedotin.
DB12274The risk or severity of adverse effects can be increased when Aducanumab is combined with Telisotuzumab vedotin.
DB12281The risk or severity of adverse effects can be increased when Luspatercept is combined with Telisotuzumab vedotin.
DB12296The risk or severity of adverse effects can be increased when GS-5745 is combined with Telisotuzumab vedotin.
DB12317The risk or severity of adverse effects can be increased when Vanucizumab is combined with Telisotuzumab vedotin.
DB12331The risk or severity of adverse effects can be increased when Labetuzumab govitecan is combined with Telisotuzumab vedotin.
DB12335The risk or severity of adverse effects can be increased when Tanezumab is combined with Telisotuzumab vedotin.
DB12342The risk or severity of adverse effects can be increased when Ensituximab is combined with Telisotuzumab vedotin.
DB12344The risk or severity of adverse effects can be increased when Fezakinumab is combined with Telisotuzumab vedotin.
DB12363The risk or severity of adverse effects can be increased when Dusigitumab is combined with Telisotuzumab vedotin.
DB12396The risk or severity of adverse effects can be increased when Fresolimumab is combined with Telisotuzumab vedotin.
DB12413The risk or severity of adverse effects can be increased when Indusatumab vedotin is combined with Telisotuzumab vedotin.
DB12456The risk or severity of adverse effects can be increased when Bococizumab is combined with Telisotuzumab vedotin.
DB12489The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Telisotuzumab vedotin.
DB12498The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Telisotuzumab vedotin.
DB12520The risk or severity of adverse effects can be increased when Plozalizumab is combined with Telisotuzumab vedotin.
DB12530The risk or severity of adverse effects can be increased when Inebilizumab is combined with Telisotuzumab vedotin.
DB12534The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Telisotuzumab vedotin.
DB12560The risk or severity of adverse effects can be increased when Blosozumab is combined with Telisotuzumab vedotin.
DB12584The risk or severity of adverse effects can be increased when Bimagrumab is combined with Telisotuzumab vedotin.
DB12589The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Telisotuzumab vedotin.
DB12609The risk or severity of adverse effects can be increased when Tovetumab is combined with Telisotuzumab vedotin.
DB12683The risk or severity of adverse effects can be increased when Lumretuzumab is combined with Telisotuzumab vedotin.
DB12698The risk or severity of adverse effects can be increased when Ibalizumab is combined with Telisotuzumab vedotin.
DB12701The risk or severity of adverse effects can be increased when Intetumumab is combined with Telisotuzumab vedotin.
DB12718The risk or severity of adverse effects can be increased when Carlumab is combined with Telisotuzumab vedotin.
DB12734The risk or severity of adverse effects can be increased when Demcizumab is combined with Telisotuzumab vedotin.
DB12773The risk or severity of adverse effects can be increased when Sifalimumab is combined with Telisotuzumab vedotin.
DB12775The risk or severity of adverse effects can be increased when Abituzumab is combined with Telisotuzumab vedotin.
DB12797The risk or severity of adverse effects can be increased when Ecromeximab is combined with Telisotuzumab vedotin.
DB12807The risk or severity of adverse effects can be increased when Naptumomab Estafenatox is combined with Telisotuzumab vedotin.
DB12815The risk or severity of adverse effects can be increased when Crotedumab is combined with Telisotuzumab vedotin.
DB12820The risk or severity of adverse effects can be increased when Concizumab is combined with Telisotuzumab vedotin.
DB12826The risk or severity of adverse effects can be increased when Depatuxizumab is combined with Telisotuzumab vedotin.
DB12844The risk or severity of adverse effects can be increased when Rontalizumab is combined with Telisotuzumab vedotin.
DB12845The risk or severity of adverse effects can be increased when Amatuximab is combined with Telisotuzumab vedotin.
DB12849The risk or severity of adverse effects can be increased when Clazakizumab is combined with Telisotuzumab vedotin.
DB12891The risk or severity of adverse effects can be increased when Ozanezumab is combined with Telisotuzumab vedotin.
DB12893The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Telisotuzumab vedotin.
DB12917The risk or severity of adverse effects can be increased when Bimekizumab is combined with Telisotuzumab vedotin.
DB12943The risk or severity of adverse effects can be increased when Milatuzumab is combined with Telisotuzumab vedotin.
DB12976The risk or severity of adverse effects can be increased when Robatumumab is combined with Telisotuzumab vedotin.
DB13017The risk or severity of adverse effects can be increased when Rovalpituzumab Tesirine is combined with Telisotuzumab vedotin.
DB13037The risk or severity of adverse effects can be increased when Namilumab is combined with Telisotuzumab vedotin.
DB13045The risk or severity of adverse effects can be increased when Racotumomab is combined with Telisotuzumab vedotin.
DB13073The risk or severity of adverse effects can be increased when Tregalizumab is combined with Telisotuzumab vedotin.
DB13127The risk or severity of adverse effects can be increased when Olokizumab is combined with Telisotuzumab vedotin.
DB13140The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Telisotuzumab vedotin.
DB13375The risk or severity of adverse effects can be increased when Edrecolomab is combined with Telisotuzumab vedotin.
DB13535The risk or severity of adverse effects can be increased when Nebacumab is combined with Telisotuzumab vedotin.
DB13886The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Telisotuzumab vedotin.
DB13923The risk or severity of adverse effects can be increased when Emicizumab is combined with Telisotuzumab vedotin.
DB13976The risk or severity of adverse effects can be increased when Sulesomab is combined with Telisotuzumab vedotin.
DB13979The risk or severity of adverse effects can be increased when Besilesomab is combined with Telisotuzumab vedotin.
DB14004The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Telisotuzumab vedotin.
DB14012The risk or severity of adverse effects can be increased when Burosumab is combined with Telisotuzumab vedotin.
DB14039The risk or severity of adverse effects can be increased when Erenumab is combined with Telisotuzumab vedotin.
DB14040The risk or severity of adverse effects can be increased when Eptinezumab is combined with Telisotuzumab vedotin.
DB14041The risk or severity of adverse effects can be increased when Fremanezumab is combined with Telisotuzumab vedotin.
DB14042The risk or severity of adverse effects can be increased when Galcanezumab is combined with Telisotuzumab vedotin.
DB14211The risk or severity of adverse effects can be increased when Fanolesomab is combined with Telisotuzumab vedotin.
DB14580The risk or severity of adverse effects can be increased when Lecanemab is combined with Telisotuzumab vedotin.
DB14597The risk or severity of adverse effects can be increased when Lanadelumab is combined with Telisotuzumab vedotin.
DB14707The risk or severity of adverse effects can be increased when Cemiplimab is combined with Telisotuzumab vedotin.
DB14724The risk or severity of adverse effects can be increased when Emapalumab is combined with Telisotuzumab vedotin.
DB14762The risk or severity of adverse effects can be increased when Risankizumab is combined with Telisotuzumab vedotin.
DB14776The risk or severity of adverse effects can be increased when Camrelizumab is combined with Telisotuzumab vedotin.
DB14778The risk or severity of adverse effects can be increased when Setrusumab is combined with Telisotuzumab vedotin.
DB14784The risk or severity of adverse effects can be increased when Gancotamab is combined with Telisotuzumab vedotin.
DB14809The risk or severity of adverse effects can be increased when Anetumab ravtansine is combined with Telisotuzumab vedotin.
DB14811The risk or severity of adverse effects can be increased when Isatuximab is combined with Telisotuzumab vedotin.
DB14824The risk or severity of adverse effects can be increased when Icrucumab is combined with Telisotuzumab vedotin.
DB14843The risk or severity of adverse effects can be increased when Codrituzumab is combined with Telisotuzumab vedotin.
DB14864The risk or severity of adverse effects can be increased when Brolucizumab is combined with Telisotuzumab vedotin.
DB14871The risk or severity of adverse effects can be increased when Xentuzumab is combined with Telisotuzumab vedotin.
DB14877The risk or severity of adverse effects can be increased when Lintuzumab is combined with Telisotuzumab vedotin.
DB14891The risk or severity of adverse effects can be increased when Vobarilizumab is combined with Telisotuzumab vedotin.
DB14897The risk or severity of adverse effects can be increased when Parsatuzumab is combined with Telisotuzumab vedotin.
DB14905The risk or severity of adverse effects can be increased when Emactuzumab is combined with Telisotuzumab vedotin.
DB14907The risk or severity of adverse effects can be increased when Bevacizumab zirconium Zr-89 is combined with Telisotuzumab vedotin.
DB14908The risk or severity of adverse effects can be increased when Refanezumab is combined with Telisotuzumab vedotin.
DB14919The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Telisotuzumab vedotin.
DB14947The risk or severity of adverse effects can be increased when Bermekimab is combined with Telisotuzumab vedotin.
DB14952The risk or severity of adverse effects can be increased when Pamrevlumab is combined with Telisotuzumab vedotin.
DB14959The risk or severity of adverse effects can be increased when Opicinumab is combined with Telisotuzumab vedotin.
DB14962The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Telisotuzumab vedotin.
DB14967The risk or severity of adverse effects can be increased when Margetuximab is combined with Telisotuzumab vedotin.
DB14988The risk or severity of adverse effects can be increased when Dalantercept is combined with Telisotuzumab vedotin.
DB14997The risk or severity of adverse effects can be increased when Pateclizumab is combined with Telisotuzumab vedotin.
DB15014The risk or severity of adverse effects can be increased when Gremubamab is combined with Telisotuzumab vedotin.
DB15022The risk or severity of adverse effects can be increased when Apomab is combined with Telisotuzumab vedotin.
DB15044The risk or severity of adverse effects can be increased when Tafasitamab is combined with Telisotuzumab vedotin.
DB15045The risk or severity of adverse effects can be increased when Ipafricept is combined with Telisotuzumab vedotin.
DB15076The risk or severity of adverse effects can be increased when Abrilumab is combined with Telisotuzumab vedotin.
DB15089The risk or severity of adverse effects can be increased when Frovocimab is combined with Telisotuzumab vedotin.
DB15090The risk or severity of adverse effects can be increased when Tezepelumab is combined with Telisotuzumab vedotin.
DB15101The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Telisotuzumab vedotin.
DB15113The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Utomilumab.
DB15118The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Zolbetuximab.
DB15135The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Ponezumab.
DB15160The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Asunercept.
DB15172The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Suvratoxumab.
DB15225The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Mitazalimab.
DB15252The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Nemolizumab.
DB15253The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Bleselumab.
DB15277The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Gedivumab.
DB15336The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Valanafusp alfa.
DB15349The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Sofituzumab vedotin.
DB15354The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Evinacumab.
DB15363The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Istiratumab.
DB15383The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Pidilizumab.
DB15397The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with GMA-161.
DB15409The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Ladiratuzumab vedotin.
DB15415The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Tomaralimab.
DB15428The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Vesencumab.
DB15432The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Pinatuzumab vedotin.
DB15441The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Lulizumab pegol.
DB15443The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Lorukafusp alfa.
DB15453The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Naratuximab emtansine.
DB15559The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Zenocutuzumab.
DB15898The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Atoltivimab.
DB15899The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Maftivimab.
DB15900The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Odesivimab.
DB15719The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Belantamab mafodotin.
DB15595The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Telisotuzumab vedotin.